---
title: "ABVC BioPharma delays annual report for fiscal year ended December 31, 2024"
url: "https://aibio.space/news/abvc-biopharma-delays-annual-report-fiscal-year-ended-december-31-2024/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-31"
section: "Distress"
tickers: "NASDAQ:ABVC"
source: "https://www.sec.gov/Archives/edgar/data/1173313/000121390025026367/ea0236076-nt10k_abvcbio.htm"
summary: "ABVC said it is still completing its audit and other disclosures. It expects to file the Form 10-K within the 15-day extension period."
---

By the aibio.space news desk.

Sources

- [ABVC BioPharma, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1173313/000121390025026367/ea0236076-nt10k_abvcbio.htm)

[ABVC](https://aibio.space/companies/abvc-biopharma/)

2025-03-31

# ABVC BioPharma delays annual report for fiscal year ended December 31, 2024

Tickers [ABVC](https://aibio.space/companies/abvc-biopharma/)

ABVC said it is still completing its audit and other disclosures. It expects to file the Form 10-K within the 15-day extension period.

## Key facts

- **Company**: ABVC BioPharma, Inc. (NASDAQ: ABVC)

- **News type**: Distress

- **Primary source**: [ABVC BioPharma, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1173313/000121390025026367/ea0236076-nt10k_abvcbio.htm)

*A supreme court building with lit columns. CC0, via rawpixel. The picture shows the field, not the companies named.*

ABVC BioPharma, Inc. said on March 31, 2025, that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, by the filing deadline.

The company filed a notification of late filing on Form 12b-25. This form tells the SEC that a report will be late and gives the company a short extension. For an annual report, the extension runs to the fifteenth calendar day after the due date.

ABVC said the delay comes from a delay it experienced in completing its financial statements and other disclosures in the Form 10-K. As a result, the company said it is still in the process of completing its audit for the fiscal year and compiling certain other required information.

The company anticipates that it will file the Form 10-K no later than the fifteenth calendar day following the prescribed filing date.

In the form, ABVC said it has filed all other periodic reports required during the preceding 12 months. It does not expect any significant change in results of operations from the prior fiscal year to be reflected in the annual report.

The Fremont, California company filed the [notice](https://www.sec.gov/Archives/edgar/data/1173313/000121390025026367/ea0236076-nt10k_abvcbio.htm) on March 31, 2025.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

ABVC

ABVC BioPharma, Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/abvc-biopharma-delays-annual-report-fiscal-year-ended-december-31-2024/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ABVC BioPharma delays annual report for fiscal year ended December 31, 2024", 2025-03-31, https://aibio.space/news/abvc-biopharma-delays-annual-report-fiscal-year-ended-december-31-2024/